Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBITDA (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of EBITDA readings, the most recent being $22.0 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 157.14% to $22.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $72.6 million, a 525.26% increase, with the full-year FY2025 number at $59.1 million, up 236.39% from a year prior.
  • EBITDA hit $22.0 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $14.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $224.1 million in Q3 2022 to a low of -$25.2 million in Q1 2022.
  • Median EBITDA over the past 5 years was $4.6 million (2022), compared with a mean of $13.8 million.
  • Biggest five-year swings in EBITDA: surged 832.01% in 2022 and later plummeted 135.69% in 2024.
  • Kiniksa Pharmaceuticals International's EBITDA stood at $4.6 million in 2022, then soared by 451.78% to $25.2 million in 2023, then plummeted by 135.69% to -$9.0 million in 2024, then skyrocketed by 259.03% to $14.3 million in 2025, then surged by 53.2% to $22.0 million in 2026.
  • The last three reported values for EBITDA were $22.0 million (Q1 2026), $14.3 million (Q4 2025), and $18.3 million (Q3 2025) per Business Quant data.